NCT01915108

Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal

Name: Clinical Trial NCT01915108
Creator: Sangjin Park
Keywords: Respiratory Complication, Remifentanil, drug, clinical trial

Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal During Emergence From Sevoflurane-remifentanil Anesthesia

Sangjin Park·ClinicalTrials.gov·drugCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Respiratory Complication
Drug/Device/Intervention: Remifentanil
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Sangjin Park
Funder: Yeungnam University College of Medicine

Timeline & enrollment

Phase: N/A
Start date: Jul 01, 2012
End date: Jun 01, 2013
Enrollment: 128 participants

Primary outcome

Number of Patients With Adverse Events Following LMA Removal

Summary

This study was designed to determine the optimal dose of remifentanil that can prevent the complications associated with the removal of LMA without delaying emergence.

ICD-10 classifications

Respiratory disorder, unspecifiedOther respiratory disordersRespiratory failure, unspecifiedOther postprocedural respiratory disordersOther specified respiratory disorders

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT01915108
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT01915108 through Pure Global AI's free database. This phase not specified trial is sponsored by Sangjin Park and is currently Completed. The study focuses on Respiratory Complication. Target enrollment is 128 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.